Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

The maturation process of oocytes remains paused for several years. Researchers from Konstanz and Göttingen have now found out which protein ensures this state is maintained over such a long period.

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

The German Research Foundation (DFG) is funding a new Emmy Noether project led by Jens Puschhof from the German Cancer Research Center (DKFZ). With this project, the junior researcher aims to decipher the role of certain intestinal bacteria in the earliest stages of colorectal cancer development and investigate how this process can be halted. The long-term goal is to develop new preventive strategies against colorectal cancer.

He researches stress and ageing at the interface of psychology and biology and is a guest at Ulm University: Professor Martin Picard from Columbia University has been awarded the Hans Kupczyk Visiting Professorship 2025, which is based in the Department of Clinical and Biological Psychology this year. On the occasion of the awarding of the visiting professorship, Picard spoke about energy as the foundation of human health of body and mind.

Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

Neurosciences - 28/02/2024

Mesh microelectrode arrays: research with brain organoids on a new level

How does the brain work? Brain organoids are derived from pluripotent stem cells and regarded as valuable model systems that can depict some aspects of neurological functioning. Dr. Peter Jones from NMI together with Dr. Thomas Rauen from the MPI for Molecular Biomedicine in Münster, has taken organoid research to a new level. His novel mesh microelectrode array (Mesh-MEA) greatly improves the growth and electrophysiological analysis of tissue.

Macrophages interacting with cytomegaloviruses - 22/02/2022

Cytomegaloviruses subvert macrophage identity

Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

Ageing is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age – a valuable tool for research on ageing and the development of new approaches in preventive medicine.

Assay to support the diagnosis of autoimmune diseases - 22/06/2022

Tracking down pathogenic immune complexes

Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.

It has only recently become known that two parallel systems of blood formation exist in the body. Researchers at the DKFZ have developed a method to examine both systems separately in mice for the first time. Their surprising finding: the majority of immune cells do not originate from classic blood stem cells in the bone marrow, but from precursor cells that are independent of blood stem cells and are already present in the embryo.

Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria.

Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.

Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.

People with metabolic dysfunction-associated steatotic liver disease (MASLD) and more so with metabolic dysfunction-associated steatohepatitis and MASLD-associated hepatic fibrosis can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular and chronic kidney disease, and cancers. Future research might be beneficial for implementing precision medicine in MASLD.

University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

Soft robots, robot systems made of soft materials, open up new perspectives for medical technology and industry. Jun.-Prof. Dr. Aniket Pal from the University of Stuttgart is conducting research into viscoelastic materials that have the potential to embed intelligent functions in soft robots. He is receiving 1.5 million euros in funding for this research as part of the Emmy Noether Program. The funding period began on September 1, 2025.

The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Mannheim University Medical Center (UMM) are presenting a method that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. This “xeno-learning” could help make surgical procedures safer and more precise in the future – without relying on human training data.

Dossier - 02/12/2013

RNA interference confidence is returning

The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

Multiple sclerosis - 12/03/2020

Direct application of biopharmaceuticals through the nose into the brain

There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.

Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

Making existing cancer therapy more efficient while significantly reducing the side effects on healthy tissue - this is the aim of a project at Aalen University. It is being funded with one million euros from the Carl Zeiss Foundation. The biophysicist and his team are developing innovative nanoparticles made of gold. The particles use radiotherapy and chemotherapy simultaneously and kill the cancer cells in a targeted manner.

A protein with contradictory properties: Despite its large negative surface charge, it has a strong tendency to take up electrons, which are also negatively charged. The researchers discovered positively charged calcium ions inside the protein very near the electrons, counteracting their charge. They see this as a natural way of handling opposing electrical charges and allowing the protein to optimally fulfill its biological function.

Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

A novel biomimetic tissue substitute combines precisely tunable mechanical properties with biological functionality and is now ready for applications in medical technology. The material was developed in the »PolyKARD« project by Fraunhofer IAP and the NMI Natural and Medical Sciences Institute. From 20.-24.04, 2026, the material will be presented together with further developments at the Hannover Messe, Fraunhofer joint booth.

Inside the fight against COVID-19 - 28/10/2020

A new immunotherapeutic agent for treating severe COVID-19 cases

Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

Affimed GmbH - 01/07/2020

"Innate cell engager" fighting against cancer

In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…

Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.

Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.

The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.

The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).

Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.

The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

Artificial intelligence: opportunities for healthcare - 06/11/2025

More than just deskwork: opportunities and obstacles for generative AI in healthcare

Generative artificial intelligence (GenAI) has enormous potential in healthcare, ranging from automating time-consuming deskwork to supporting diagnoses. It is not just for the big players; there are also cost-effective ways for smaller companies and institutions to utilize GenAI.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

Researchers have designed synthetic and inducible proteins that bind to bright fluorescent dyes with high specificity and affinity, significantly expanding the toolkit for multicolour imaging of proteins inside cells.

Biochip systems - 02/09/2020

Miniature organs with great potential

Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…

Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.

Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

Konstanz researchers identify an enzyme that plays a role in the migration of cells in our body - not only during normal tissue formation and wound healing, but also when tumor cells metastasize. This makes the enzyme an interesting candidate for potential future therapeutic approaches.

Dossier - 02/06/2014

Bioanalysis techniques for the characterization of biological material

Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind…

An interdisciplinary research group combining mechanical engineering and biotechnology has taken up its work at the Institute for Molecular Systems Engineering and Advanced Materials (IMSEAM) of Heidelberg University. The team under the direction of Dr Kai Melde will pursue an innovative approach to biofabrication – 3D cell culture using ultrasound. Tools are being developed that can be used as an alternative to or enhancement for 3D printing.

Transcranial magnetic stimulation (TMS) - 10/12/2024

sync2brain: using magnetic waves to combat depression

In cases where standard therapies for mental illnesses such as depression prove ineffective, transcranial magnetic stimulation (TMS) offers a promising alternative. This method uses magnetic pulses to stimulate specific regions of the brain. The company sync2brain has developed a system that leverages EEG measurements to tailor stimulation to each patient's unique brain wave patterns, that may significantly enhance the therapy's…

Like all viruses, the Ebola virus is dependent on host cells in order to replicate. Researchers at Heidelberg University Hospital, in collaboration with colleagues from the Friedrich Loeffler Institute, have been able to show for the first time using state-of-the-art imaging techniques how the replication compartments of the Ebola virus change during replication in infected cells.

Prof. Dr Simon Elsässer will be awarded one of this year’s Alexander von Humboldt Professorships in Berlin on 12 May 2026. With funding of five million euros, Elsässer will strengthen Freiburg’s research focus ‘Signals of Life’ over the next five years. In this interview, he discusses complex decision-making processes in cells, the significance of signals and what makes the research environment in Freiburg so special.

Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.

After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.

Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.

During the growth and development of living organisms, different types of cells must come into contact with each other in order to form tissues and organs together. A small team working with Prof. Dr. Anne Classen of the Excellence Cluster CIBSS of the University of Freiburg has discovered that complex changes in form, or morphogenesis, during development are driven exclusively via the affinity of cells to each other.

How are proteins in our cells modified while they are still being synthesized? An international team of researchers from the University of Konstanz, Caltech, and ETH Zurich has deciphered the molecular mechanism of this vital process.

Scientists at the Max Planck Institute for Intelligent Systems developed a single-cell green microalgae coated with magnetic material. This miniature robot was put to the test: would the microalgae with its magnetic coating be able to swim through narrow spaces and, additionally, in a viscous fluid that mimics those found in the human body? Would the tiny robot be able to fight its way through these difficult conditions?

Dossier - 28/04/2014

Data mining new opportunities for medicine and public health

Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput, visualisation methods and telemedical applications.

Cancer researcher Dr Alexandra Niedermayer from the Ulm Children’s and Adolescents’ Clinic has been awarded the Franziska Kolb Prize, worth 8,000 euros, by the Ulm University Foundation. The 32-year-old researches aggressive forms of blood cancer and, using modern techniques, has identified an effective, personalised treatment approach.

Stem cell research - 14/03/2024

Using organoids to gain a better clinical understanding of pancreatic cancer

Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

How can camera images be used during minimally invasive surgeries to assess whether the operated organ is sufficiently perfused with blood? Scientists from the German Cancer Research Center (DKFZ) and the Städtisches Klinikum Karlsruhe have now succeeded in automatic monitoring of ischemia during a kidney surgery using only the optical properties of the tissue and not relying on injection of contrast agent.

The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.